7月7日 - ** 花旗将a2 Milk在澳大利亚上市的股票 A2M.AX 的目标价上调4%至7澳元，维持“中性”评级
** 该券商还将a2 Milk 2026、2027和2028财年的核心净利润（NPAT）预期分别上调3%、4%和3%
** 这家总部位于新西兰的乳业巨头周二 (link) 表示，影响其核心“中国标签”IMF产品供应的因素已基本解决；并补充称，目前预计2026财年净利润将高于去年
** 花旗认为2027财年市场共识盈利存在下行风险，并认为在市场准入受阻后，a2在品牌投资和重塑市场份额方面“任重道远”
** 该券商认为，a2将受益于多项基本面利好因素，包括地域和产品类别的扩张
** 花旗表示，在转为更乐观的看法之前，关键在于观察a2能以多快的速度恢复市场份额(以及为此付出何种代价)
** 截至上一交易日收盘，a2在澳交所（ASX）的股价今年以来累计下跌16.3%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.